Satellos Bioscience Switches BASECAMP Phase 2 Primary Endpoint To MRI Fat Fraction Following FDA Feedback
Fat fraction, together with clinical endpoints, may support a potential accelerated approval pathway for forazapadinProtocol amendment submitted to implement the new primary efficacy endpointTopline 12-week
Satellos Bioscience changed how it will measure success in its medicine test. The company now uses a body scan measurement, which might help get approval faster from health officials.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.